IL212024A0 - Anhydrate and hydrate forms of strontium ranelate - Google Patents

Anhydrate and hydrate forms of strontium ranelate

Info

Publication number
IL212024A0
IL212024A0 IL212024A IL21202411A IL212024A0 IL 212024 A0 IL212024 A0 IL 212024A0 IL 212024 A IL212024 A IL 212024A IL 21202411 A IL21202411 A IL 21202411A IL 212024 A0 IL212024 A0 IL 212024A0
Authority
IL
Israel
Prior art keywords
anhydrate
hydrate forms
strontium ranelate
ranelate
strontium
Prior art date
Application number
IL212024A
Original Assignee
Ratiopharm Gmbh
Wolfgang Albrecht
Gertrud Auer
Ramesh Matioram Gidwani
Christian Janssen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh, Wolfgang Albrecht, Gertrud Auer, Ramesh Matioram Gidwani, Christian Janssen filed Critical Ratiopharm Gmbh
Publication of IL212024A0 publication Critical patent/IL212024A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic System

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL212024A 2008-09-29 2011-03-29 Anhydrate and hydrate forms of strontium ranelate IL212024A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08017141 2008-09-29
IN593CH2009 2009-03-16
PCT/EP2009/062439 WO2010034806A1 (en) 2008-09-29 2009-09-25 Anhydrate and hydrate forms of strontium ranelate

Publications (1)

Publication Number Publication Date
IL212024A0 true IL212024A0 (en) 2011-06-30

Family

ID=41394902

Family Applications (1)

Application Number Title Priority Date Filing Date
IL212024A IL212024A0 (en) 2008-09-29 2011-03-29 Anhydrate and hydrate forms of strontium ranelate

Country Status (6)

Country Link
EP (1) EP2346846A1 (en)
KR (1) KR20110066197A (en)
CN (1) CN102227419A (en)
IL (1) IL212024A0 (en)
RU (1) RU2011116926A (en)
WO (1) WO2010034806A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1398542B1 (en) 2010-03-05 2013-03-01 Chemelectiva S R L PROCESS FOR THE PREPARATION OF A POLIMORFO
WO2012046251A2 (en) * 2010-10-08 2012-04-12 Glenmark Generics Limited Novel form of ranelic acid
WO2012143932A1 (en) * 2011-04-21 2012-10-26 Shilpa Medicare Limited Crystalline strontium ranelate form-s
CZ2011320A3 (en) 2011-05-30 2012-12-12 Zentiva, K.S. Stable crystalline form of X strontium renelate
CN102321068B (en) * 2011-08-01 2013-01-23 山东铂源药业有限公司 Method for preparing strontium ranelate
EP2641905A1 (en) 2012-03-23 2013-09-25 Urquima S.A. Solid forms of strontium ranelate and processes for their preparation
US8569514B1 (en) 2012-05-17 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of strontium ranelate
WO2013175270A1 (en) * 2012-05-25 2013-11-28 Fleming Laboratories Limited Improved process for the preparation of strontium ranelate hydrates and new polymorphic form of monohydrate
CN102764235B (en) * 2012-06-21 2017-09-05 浙江华海药业股份有限公司 Strontium ranelate dry suspension and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651497B1 (en) 1989-09-01 1991-10-25 Adir NOVEL SALTS OF BIVALENT METALS OF N, N-DI ACID (CARBOXYMETHYL) AMINO-2 CYANO-3 CARBOXYMETHYL-4 CARBOXY-5 THIOPHENE, THEIR PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2875807B1 (en) 2004-09-30 2006-11-17 Servier Lab ALPHA CRYSTALLINE FORM OF STRONTIUM RANELATE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2921367B1 (en) * 2007-09-26 2009-10-30 Servier Lab NEW PROCESS FOR THE SYNTHESIS OF STRONTIUM RANELATE AND ITS HYDRATES

Also Published As

Publication number Publication date
CN102227419A (en) 2011-10-26
WO2010034806A1 (en) 2010-04-01
EP2346846A1 (en) 2011-07-27
KR20110066197A (en) 2011-06-16
RU2011116926A (en) 2012-11-10

Similar Documents

Publication Publication Date Title
IL212024A0 (en) Anhydrate and hydrate forms of strontium ranelate
ZA201308527B (en) Forms of rifaximin and uses thereof
HK1172896A1 (en) Compounds and methods of use
GB2478477B (en) Downhole communication devices and methods of use
HK1161094A1 (en) Compounds and methods of use
SG10201405568UA (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
IL213596A0 (en) Heterocyclic compounds and methods of use
GB2428544B (en) Configuration of remote devices
IL196181A0 (en) Substituted n-phenylmethyl-5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
EP2464227A4 (en) Compounds and methods of use thereof
SI2042497T1 (en) Method for producing strontium ranelate and its hydrates
EG25743A (en) Compositions containing amide surfactants and methods for inhiting the formation of hydrate agglamerates
IL208754A (en) Benzothiophene compounds and use thereof
EP2134352A4 (en) Wnt compositions and methods of use thereof
GB0812890D0 (en) Compositions and methods of making compositions
HRP20180569T1 (en) Accelerated hydrate formation and dissociation
EP2257516A4 (en) Methods of making cyclododecatriene and methods of making laurolactone
PL2179657T3 (en) Gas-effusing compositions and methods of making same
EP2181328A4 (en) Methods of using ret nanosensors
GB0724953D0 (en) Methods of peptide modification
HK1151242A1 (en) Mntf peptide compositions and methods of use mntf
EP2291347A4 (en) Manufacture and use of alkyl p-toluates
ZA200810726B (en) Substituted N-Phenylmethyl -5-OXO-Proline-2-Amides AS P2X7-Receptor Antagonists and their methods of use
GB0605087D0 (en) Neutralisation Of Strong Winds
GB0906533D0 (en) Self-adhesive tile cover and method of use